Tern Plc Tranche One of Device Authority Fund Raise Now Complete

Tern plc

Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that, further to the Company’s announcement of 27 December 2023, Tranche One (“T1”) of the Device Authority Fund Raise has now completed.  Through T1 Device Authority has received US$4.0 million.

A further announcement will be made by Tern Plc in due course upon completion of the Second Tranche (“T2”) of the Device Authority Fund Raise. T2 totals US$3.3 million and is contingent on approval pursuant to the National Security and Investment Act 2021 (“NASI”) and acceptance of the approval by Ten Eleven Ventures.

Unless otherwise stated, defined terms should be given the meaning given to them in the announcement made on 27 December 2023.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Tern raises £222,000 through share placing

Tern has raised £222,000 before expenses through a placing of 37 million new ordinary shares at 0.60 pence per share, with admission to AIM expected on or around 22 May 2026.

FundamentalXR targets surgical readiness for advanced eye therapies

FundamentalXR is targeting surgical readiness for advanced eye therapies with immersive simulation designed to support real-world adoption.

Search